CLINICAL
PHARMACOLOGY OF DRUGS USED IN THE TREATMENT OF ASTHMA
Asthma
is best thought of as a disease in two time domains. In the present domain, it
is important for the distress it causes—cough, nocturnal awakenings, and
shortness of breath that interferes with the ability to exercise or to pursue
desired activities. For mild asthma, occasional inhalation of a bronchodilator
may be all that is needed. For more severe asthma, treatment with a long-term
controller, like an inhaled corticosteroid, is necessary to relieve symptoms
and restore function. The second domain of asthma is the risk it presents of
future events, such as exacerbations, or of progressive loss of pulmonary
function. A patient’s satisfaction with his or her ability to control symptoms
and maintain function by frequent use of an inhaled β2 agonist does not mean that the risk of future
events is also controlled. In fact, use of two or more canisters of an inhaled β agonist per month is
a marker of increased risk of asthma fatality. The challenges of assessing
severity and adjusting therapy for these two domains of asthma are different.
For relief of distress in the present domain, the key information can be
obtained by ask-ing specific questions about the frequency and severity of
symp-toms, the frequency of use of an inhaled β2 agonist for relief of symptoms, the frequency
of nocturnal awakenings, and the ability to exercise. Estimating the risk for
future exacerbations is more difficult. In general, patients with poorly
controlled symptoms in the present have a heightened risk of exacerbations in
the future, but some patients seem unaware of the severity of their underlying
airflow obstruction (sometimes described as “poor perceivers”) and can be
identified only by measurement of pulmonary func-tion, as by spirometry.
Reductions in the FEV1 correlate with heightened risk of attacks of
asthma in the future. Other possible markers of heightened risk are unstable
pulmonary function (large variations in FEV1 from visit to visit,
large change with broncho-dilator treatment), extreme bronchial reactivity, or
high numbers of eosinophils in sputum or of nitric oxide in exhaled air.
Assessment of these features may identify patients who need increases in
therapy for protection against exacerbations.
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2024 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.